Protalix BioTherapeutics, Inc.
PLX · NYSE American · United States
Share price · PLX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PLX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+9.4%
- 10 Nov 2026+11.3%
- 14 Aug 2026-5.9%
Nothing announced by PLX that day or the session before.
- 13 Aug 2026-9.9%
- 12 Aug 2026+7.8%
- 18 Jun 2026+9.9%
Nothing announced by PLX that day or the session before.
- 5 May 2026-8.0%
Nothing announced by PLX that day or the session before.
- 18 Mar 2026-20.8%
- 11 Feb 2026+8.1%
- 2 Feb 2026+11.1%
Share of unusual movement by asset
For each asset, the share of PLX's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Alpha-galactosidase A (GLA / α-Gal A)Protein / enzyme therapeutic | Fabry Disease | |
| Phase 2 | Uric acidProtein / enzyme therapeutic | Gout Severe Refractory Gout |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $22M | $6.9M | $22M | —$3.9M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $20M | $4.3M | $27M | —-$10M operating cash flow | report ↗ |
| 2026-Q1 | $34M | $5.4M | $41M | —$22M operating cash flow | report ↗ |
| 2025-Q3 | $18M | $4.5M | $14M | —-$3.7M operating cash flow | report ↗ |
| 2025-Q2 | $16M | $6.0M | $18M | —-$5.2M operating cash flow | report ↗ |
| 2025-Q1 | $10M | $3.5M | $19M | $3.6M-$5.1M operating cash flow | report ↗ |
| 2024-Q3 | $18M | $3.0M | $27M | —$4.1M operating cash flow | report ↗ |
| 2024-Q2 | $13M | $3.0M | $23M | $2.2M-$3.6M operating cash flow | report ↗ |
| 2024-Q1 | $3.8M | $2.9M | $27M | $4.6M$4.2M operating cash flow | report ↗ |
| 2023-Q3 | $10M | $3.7M | $20M | $1.9M-$6.9M operating cash flow | report ↗ |
| 2023-Q2 | $35M | $4.5M | $48M | —$5.0M operating cash flow | report ↗ |
| 2023-Q1 | $9.6M | $5.8M | $33M | $3.1M-$3.0M operating cash flow | report ↗ |
| 2022-Q3 | $14M | $7.4M | $11M | $3.6M-$9.2M operating cash flow | report ↗ |
| 2022-Q2 | $8.8M | $7.6M | $12M | $5.3M-$7.4M operating cash flow | report ↗ |
| 2022-Q1 | $16M | $8.8M | $17M | $2.3M-$5.8M operating cash flow | report ↗ |
| 2021-Q3 | $12M | $7.3M | $11M | $4.2M-$1.9M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $53M | $20M | $15M | $1.6M-$12M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($101K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-03 | Schwartz Aharon · director | Award / grant (derivative) | 17,000 | — | — | Form 4 |
| 2026-09-03 | Schwartz Aharon · director | Award / grant (derivative) | 8,500 | — | — | Form 4 |
| 2026-09-03 | Forster Eliot · director | Award / grant (derivative) | 17,000 | — | — | Form 4 |
| 2026-09-03 | Ben Zvi Shmuel · director | Award / grant (derivative) | 17,000 | — | — | Form 4 |
| 2026-09-03 | Bar-Shalev Amos · director | Award / grant (derivative) | 17,000 | — | — | Form 4 |
| 2026-09-03 | Bashan Dror · director, PRESIDENT AND CEO | Award / grant (derivative) | 320,000 | — | — | Form 4 |
| 2026-09-03 | Boudes Pol F · director | Award / grant (derivative) | 17,000 | — | — | Form 4 |
| 2026-09-03 | Melincoff Gwen A · director | Award / grant (derivative) | 17,000 | — | — | Form 4 |